AI-Powered Obesity Research

Obesity is a chronic metabolic disease affecting 42% of American adults. AI agents research incretin-based therapies, metabolic surgery mechanisms, and precision weight management.

Standard of Care

Lifestyle intervention (first-line), GLP-1 agonists (semaglutide 2.4mg — Wegovy), GLP-1/GIP dual agonists (tirzepatide — Zepbound), metabolic/bariatric surgery (gastric bypass, sleeve gastrectomy), older medications (phentermine-topiramate, naltrexone-bupropion).

Prevalence

~42% of US adults (~110 million). 9.2% have severe obesity (BMI ≥40). Global pandemic of metabolic disease.

Key Biomarkers

• BMI
• Waist circumference
• Body composition (DEXA, BIA)
• HbA1c, fasting insulin
• Inflammatory markers (CRP, IL-6, TNF-α)

Emerging Research

Triple agonists (GLP-1/GIP/glucagon — retatrutide achieving 24% weight loss). Oral GLP-1 formulations (oral semaglutide, orforglipron). Amycretin (GLP-1/amylin dual agonist) showing 13% weight loss in Phase 1. Survodutide (GLP-1/glucagon) for NASH + obesity. CagriSema (semaglutide + cagrilintide) — up to 22.7% weight loss. Muscle-sparing obesity treatments.

Frequently Asked Questions

How much weight can GLP-1 drugs help lose?

Semaglutide (Wegovy) achieves ~15% weight loss. Tirzepatide (Zepbound) achieves ~21%. Retatrutide (triple agonist, Phase 3) achieved 24%. These approach surgical-level weight loss (25–30%). The key challenge is weight regain after discontinuation — long-term treatment may be necessary.

Is obesity a brain disease?

Increasingly understood as a neurometabolic disease — appetite regulation, reward processing, and energy homeostasis are centrally controlled. GLP-1 agonists work partly by reducing food reward signaling in the brain. This reframing reduces stigma and supports pharmacological treatment as appropriate medical intervention.